News - Neurological, Cymbalta

Filter

Current filters:

NeurologicalCymbalta

Popular Filters

Lilly/Boehringer Ingelheim's Cymbalta now fibromyalgia market leader in USA

22-07-2012

US drug major Eli Lilly (NYSE: LLY) and German independent Boehringer Ingelheim's Cymbalta (duloxetine)…

Boehringer IngelheimCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Eli Lilly gains six months US pediatric exclusivity for Cymbalta

08-07-2012

US drug major Eli Lilly (NYSE: LLY) announced that it has met the US Food and Drug Administration requirements…

CymbaltaEli LillyNeurologicalNorth AmericaPharmaceuticalRegulation

Global pain management drugs market to see moderate growth as generic share continues to rise

24-11-2011

In 2010, the global pain management market was worth approximately $28.6 billion, representing a compound…

CelebrexCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalPfizerPharmaceutical

Pfizer’s Pristiq sees private plan formulary access similar to Lilly’s Cymbalta

31-08-2011

In the USA, similar percentages of private health plan lives have formulary access to Pfizer’s (NYSE:…

CymbaltaEli LillyHealthcareNeurologicalNorth AmericaPfizerPharmaceuticalPricingPristiq

Back to top